<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885403</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-A 12-117</org_study_id>
    <nct_id>NCT01885403</nct_id>
  </id_info>
  <brief_title>Acute Congestive Heart Failure</brief_title>
  <acronym>AcuteCHF</acronym>
  <official_title>Non-Invasive Pulmonary Monitoring in Patients With Cardiogenic Pulmonary Congestion and Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Technology Aachen Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the feasibility of collecting respiratory parameters&#xD;
      during recompensation following ADHF (Acute Decompensated Heart Failure)with non-invasive&#xD;
      measurements. This could lead to a better understanding of how respiratory parameters may&#xD;
      change during re-compensation therapy and could also be a comfortable method for patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a single-center, open, interventional, observational study according&#xD;
      to clause §23b of the German Medical Device Act (MPG). The study will recruit 50 patients&#xD;
      suffering from cardiogenic pulmonary congestion and edema including ambulant patients and&#xD;
      patients of intensive care.&#xD;
&#xD;
      We will investigate whether respiratory parameters during re-compensation are related to the&#xD;
      therapy effects and changes in pulmonary congestion status. This study will collect data in&#xD;
      an observational and clinical setting in the re-compensation phase of ADHF.&#xD;
&#xD;
      Correlation between measured lung and respiratory parameters and standard clinical parameters&#xD;
      characterizing stages of re-compensation will be undertaken. Standard clinical parameters may&#xD;
      include diuretics and other cardiac medication dose frequency, weight, heart rate,&#xD;
      respiratory rate, chest x-rays (when routinely performed), symptoms such as shortness of&#xD;
      breath or fatigue, biomarkers such as brain natriuretic peptide (BNP), stroke volume, cardiac&#xD;
      output, and oxygen requirements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between current standard clinical assessment of re-compensation and measured respiratory parameters</measure>
    <time_frame>about 3 months</time_frame>
    <description>stationary as well as ambulant patients with acute decompensation receive clinical standard measurements and will be measured with the help of non- invasive technology such as respiratory profile and gaz analysis, bioimpedance spectroscopy. Patients will be measured at baseline and 2 times at ward if applicable and at 3 months follow up visit. Measurements will take 1:30 hours per visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Decompensated Heart Failure (ADHF)</condition>
  <condition>Acute Cardiogenic Pulmonary Edema (ACPE)</condition>
  <arm_group>
    <arm_group_label>Respiratory Parameters Measurements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non-invasive respiratory parameter measurements</intervention_name>
    <arm_group_label>Respiratory Parameters Measurements</arm_group_label>
    <other_name>Philips Respironics BiPAP Synchrony, Bioimpedance ImpediMed- SFB7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, ages 18-75&#xD;
&#xD;
          2. Able and willing to provide written informed consent or not able to give informed&#xD;
             consent because of mechanical respiration&#xD;
&#xD;
          3. Diagnosis of acute or chronic decompensated heart failure with pulmonary congestion or&#xD;
             edema&#xD;
&#xD;
          4. Systolic blood pressure &gt;80 mm Hg at time of enrollment&#xD;
&#xD;
          5. Resting pulse oximetry (SpO2) at the time of enrollment of at least 88% at 21% iron&#xD;
             oxides (FeO2)&#xD;
&#xD;
          6. Agreement to be measured with the study devices according to study protocol by patient&#xD;
             or legal representative&#xD;
&#xD;
          7. Left ventricular ejection fraction (LVEF) &lt; 40% in 3D- Echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active participation in another interventional research study&#xD;
&#xD;
          2. Surgery of the upper airway, nose, sinus or middle ear within the last 90 days&#xD;
&#xD;
          3. Major medical or psychiatric condition that would interfere with the demands of the&#xD;
             study or the ability to complete the study. For example, severe unstable chronic lung&#xD;
             disease such as obstructive (FEV1/FVC ≤ 30%), or restrictive (FVC &lt; 50% predicted)&#xD;
             lung disease, neuromuscular disease, cancer, or renal failure&#xD;
&#xD;
          4. Unable to use PAP therapies due to physical issues (e.g. facial structural&#xD;
             abnormalities) or cognitive issues (e.g. dementia)&#xD;
&#xD;
          5. Participants in whom positive airway pressure (PAP) therapy is medically&#xD;
             contraindicated.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic ≥200 mm Hg/diastolic ≥120 mm Hg)&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Lactation&#xD;
&#xD;
          9. Implanted pacemaker / Cardiac Resynchronization Therapy (CRT) / implantable&#xD;
             cardioverter-defibrillator (ICD) except for Medtronic devices with Opti Vol Algorithm&#xD;
&#xD;
         10. Incompetent patients or patients who, in the judgment of the investigator, are too&#xD;
             unstable or are otherwise not capable of performing study procedures&#xD;
&#xD;
         11. Post-partum cardiomyopathy&#xD;
&#xD;
         12. Hypertrophic&#xD;
&#xD;
         13. Primary mitral valve stenosis&#xD;
&#xD;
         14. Patients requiring more than 50% supplemental oxygen or patients requiring more than 4&#xD;
             lpm oxygen&#xD;
&#xD;
         15. Patients with persistent ventricular arrhythmias (Premature ventricular coupling,&#xD;
             periods of ventricular tachycardia)&#xD;
&#xD;
         16. Patients chronically classified (prior to admission) as New York Heart Association&#xD;
             (NYHA) Class IV or American Heart Association Class D heart failure&#xD;
&#xD;
         17. Patients with glomerular filtration rate (GFR) &lt;30 or obligatory dialysis&#xD;
&#xD;
         18. Resting respiratory rate &gt;30 breaths per minute&#xD;
&#xD;
         19. Patients requiring mechanical ventilation or patients with an artificial airway&#xD;
             (endotracheal or tracheostomy tube)&#xD;
&#xD;
         20. Patients with carbon monoxide toxicity&#xD;
&#xD;
         21. Patients with severe sepsis (defined as also an organ dysfunction due to an infection&#xD;
             according to the Guidelines of the German Association of Sepsis, February 2010)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Schröder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Pneumology, Angiology and Intensive Care, Internal Medicine I (MK I), University Hospital Aachen (UKA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jörg Schröder, MD</last_name>
    <phone>+4924180</phone>
    <phone_ext>89391</phone_ext>
    <email>jschröder@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sigrid Gloeggler, M.Sc.</last_name>
    <phone>+4924180</phone>
    <phone_ext>80202</phone_ext>
    <email>sgloeggler@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Aachen, Department of Cardiology</name>
      <address>
        <city>Aachen</city>
        <state>Northrhine-Westfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Schröder, MD</last_name>
      <phone>+4924180</phone>
      <phone_ext>89391</phone_ext>
      <email>jschröder@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sigrid Gloeggler, M.Sc.</last_name>
      <phone>+4924180</phone>
      <phone_ext>80202</phone_ext>
      <email>sgloeggler@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jörg Schröder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Kersten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Napp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrin Kersten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Cardiogenic Pulmonary Edema,</keyword>
  <keyword>Acute Decompensated Heart Failure,</keyword>
  <keyword>BiLevel Positive Airway Pressure,</keyword>
  <keyword>Continuous Positive Airway Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

